Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-1919.68%
operating margin TTM
-2033.39%
revenue TTM
758.30 Thousand
revenue per share TTM
0.12$
valuation ratios | |
|---|---|
| pe ratio | -0.63 |
| peg ratio | 0.00 |
| price to book ratio | 1.80 |
| price to sales ratio | 7.23 |
| enterprise value multiple | -0.68 |
| price fair value | 1.80 |
profitability ratios | |
|---|---|
| gross profit margin | 89.03% |
| operating profit margin | -2033.39% |
| pretax profit margin | -1907.18% |
| net profit margin | -1919.68% |
| return on assets | -139.91% |
| return on equity | -139.47% |
| return on capital employed | -232.01% |
liquidity ratios | |
|---|---|
| current ratio | 2.56 |
| quick ratio | 2.56 |
| cash ratio | 1.29 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 5,403.56 |
| cash conversion cycle | -5,403.56 |
| receivables turnover | 0.00 |
| payables turnover | 0.07 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.07 |
| debt equity ratio | 0.14 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.12 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -19.46 |
cash flow ratios | |
|---|---|
| free cash flow per share | -8.19 |
| cash per share | 5.29 |
| operating cash flow per share | -8.14 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -19.46 |
| short term coverage ratios | -22.94 |
| capital expenditure coverage ratio | -182.98 |
Frequently Asked Questions
When was the last time Aligos Therapeutics, Inc. (NASDAQ:ALGS) reported earnings?
Aligos Therapeutics, Inc. (ALGS) published its most recent earnings results on 07-05-2026.
What is Aligos Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Aligos Therapeutics, Inc. (NASDAQ:ALGS)'s trailing twelve months ROE is -139.47%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Aligos Therapeutics, Inc. (ALGS) currently has a ROA of -139.91%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ALGS's net profit margin stand at?
ALGS reported a profit margin of -1919.68% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ALGS's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.56 in the most recent quarter. The quick ratio stood at 2.56, with a Debt/Eq ratio of 0.14.